42 filings
Page 2 of 3
8-K
50889
3 Jun 21
Other Events
8:08am
8-K
8eji ygectnl3sgya
6 May 21
Oyster Point Pharma Reports First Quarter 2021 Financial Results and Recent Business Highlights
4:03pm
8-K
7a9nsu lu
5 Apr 21
Oyster Point Pharma Announces New Appointment to Board of Directors
6:15am
8-K
oconl0din
2 Mar 21
U.S. Food and Drug Administration (FDA) has stated that it does not intend to hold an advisory committee meeting to discuss this application
8:17am
8-K
3dv0enfe rmf7qk75
18 Feb 21
Oyster Point Pharma Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights
4:01pm
8-K
gxity
18 Dec 20
Other Events
7:16am
8-K
nau32t am
2 Dec 20
Planned enrollment of the first patient in the OLYMPIA Phase 2 study in 1H 2021
9:37am
8-K
h94pkqmk
5 Nov 20
Entry into a Material Definitive Agreement
5:24pm
8-K
ihyvc969
5 Nov 20
Oyster Point Pharma Reports Third Quarter 2020 Financial Results and Recent Business Highlights
4:01pm
8-K
tyuqm0z jug7r
9 Oct 20
Oyster Point Pharma Announces Board of Directors Leadership Changes and New
8:01am
8-K
rfezj mx1
5 Aug 20
Oyster Point Pharma Reports Second Quarter 2020 Financial Results and Recent Business Highlights
7:02am
8-K
9rj3uy
9 Jun 20
Regulation FD Disclosure
12:00am
8-K
ljufjgqs slxsv612l
5 Jun 20
Submission of Matters to a Vote of Security Holders
4:17pm
8-K
pbmyqcjml 5i70
15 May 20
Oyster Point Pharma Announces Pricing of an Upsized Offering of Common Stock
8:00am
8-K
zzig qhfirald
11 May 20
Other Events
6:10am
8-K
xmzn42
11 May 20
Oyster Point Pharma Reports First Quarter 2020 Financial Results and Recent Business Highlights
6:07am
8-K
rrvak4 hyhevwzk
30 Mar 20
ONSET-2 Phase 3 Top-Line Data Expected by End of Q2 2020
7:33am
8-K
7o7cm1vbqao7 mo6oe5
27 Feb 20
Oyster Point Pharma Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Business Highlights
4:09pm
8-K
6oa9apf0b3kj0e2m
14 Jan 20
Regulation FD Disclosure
8:01am
8-K
pswuvrd1vf2
13 Jan 20
Regulation FD Disclosure
8:00am